U.S. markets open in 9 hours 27 minutes
  • S&P Futures

    4,390.75
    -3.75 (-0.09%)
     
  • Dow Futures

    34,895.00
    -58.00 (-0.17%)
     
  • Nasdaq Futures

    14,927.75
    -20.00 (-0.13%)
     
  • Russell 2000 Futures

    2,190.80
    +4.10 (+0.19%)
     
  • Crude Oil

    72.12
    +0.47 (+0.66%)
     
  • Gold

    1,806.30
    +6.50 (+0.36%)
     
  • Silver

    24.84
    +0.20 (+0.80%)
     
  • EUR/USD

    1.1826
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.2340
    -0.0420 (-3.29%)
     
  • Vix

    19.36
    +1.78 (+10.13%)
     
  • GBP/USD

    1.3875
    -0.0003 (-0.02%)
     
  • USD/JPY

    109.8040
    +0.0370 (+0.03%)
     
  • BTC-USD

    39,938.22
    +3,184.96 (+8.67%)
     
  • CMC Crypto 200

    933.84
    +57.61 (+6.57%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,607.57
    -362.65 (-1.30%)
     

Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs

·4 min read
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs

Biogen (NASDAQ: BIIB) stock rocketed to a six-year high earlier this week on news that its therapy, aducanumab, was the first Alzheimer's drug approved in nearly 20 years by the U.S. Food and Drug Administration (FDA). This is a huge deal, not only for Alzheimer's patients, but for Biogen and its shareholders. There are two other biotech stocks, however, whose recent breakthroughs could drive the profits for years to come, and they are still priced modestly -- for now.